Archimedes Pharma
Reading
About Archimedes Pharma
Archimedes Pharma Limited operates as a specialty pharmaceutical company. Its products include Gliadel, for high grade glioma; Zomorph, an oral sustained release morphine product for cancer pain; Nozinan that treats nausea and vomiting in cancer patients; Pabrinex, a formulation of vitamins B and C for alcoholics experiencing acute withdrawal; and Nasalfent, an intranasal fentanyl for relief of cancer pain. The company was founded in 2004 and is headquartered in Reading, the United Kingdom. It has operations in the United Kingdom, France, and Germany.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $99.0M
- Funding stage: M&A
- Last round: Series C (Apr 2010)
- Website: archimedespharma.com
- Phone: 441189315051
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/archimedes-pharma-2639848 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.